News
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,
Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
9hon MSN
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ...
Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much ...
Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback